Technologies

Antibacterial phosphine complex

"Effective antimicrobial activity, reduced toxicity, and the possibility of treating current drug-resistant tuberculosis"

This technique includes a new class of antitubercle bacilli active compounds and their obtaining process. The new compounds have the potential to treat the current drug-resistant strains. The compound can be used for the preparation of tuberculosis drugs, antiseptics and disinfectants.

Question:. As that numb of drug-resistant bacteria used for routine treatment of tuberculosis increase, it is necessary to improve the activity of existing drugs or to develop new active drug.

Proposed solution: The compounds developed have proven to be efficient, Extracorporeal extracorporeal The main cause of tuberculosis, Mycobacterium tuberculosis Sensitive to current treatment regimens and clinical isolates of single and multi-drug resistance.

Market potential
According to the World Health Organization, 1.8 million people die of tuberculosis each year. In the same year, 8.7 million new cases of disease were reported worldwide; 4.9% of them were from drug-resistant strains. Expenditure on tuberculosis treatment and control in high-incidence countries is expected to reach $2.6 billion in 2010, 68 per cent of which is related to Russia and South Africa. In Brazil, spending is projected at $99 million in 2010, more than 90 per cent of government spending (Global Tuberculosis Control, World Health Organization, 2010).

Http://unesp.tecnologypublisher.com/files/nit-055-09--comp.-inositol phosphate-com-ativ.pdf

Http://unesp.tecnologypublisher.com/files/nit-055-09--phosphinic_complex_antimyc_activity1. Pdf